What's new

Human medicines European public assessment report (EPAR): Buprenorphine Neuraxpharm, buprenorphine, Date of authorisation: 19/12/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Buprenorphine Neuraxpharm, buprenorphine, Date of authorisation: 19/12/2024, Revision: 1, Status: Authorised

May 16, 2025 - 15:22
 0
Human medicines European public assessment report (EPAR): Buprenorphine Neuraxpharm, buprenorphine, Date of authorisation: 19/12/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Buprenorphine Neuraxpharm, buprenorphine, Date of authorisation: 19/12/2024, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Incyte's Zynyz secures approvals in anal cancer 4 years after FDA rejection

Next Article

M&S cyber-attack: lessons on crisis management

Related Posts

Human medicines European public assessment report (EPAR): Givlaari, givosiran, Date of authorisation: 02/03/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

May 8, 2025  0

Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 March 2025, European Medicines Agency, Amsterdam, the Netherlands, from 10 March 2025 to 13 March 2025

Pharmacovigilance Risk Assessment Committee (PRAC): 10 ...

May 8, 2025  0

Annex - National provisions for SMEs applicable to the ...

May 15, 2025  0